Edmondo Robinson, MD
Chief Digital Officer
Barriers to access for immuno-oncology therapies like CAR-T are threatening the promise of these lifesaving treatments. A small number of approved therapies that often face manufacturing challenges, the limited number of treatment centers, the high costs, and the post-treatment monitoring requirements make bringing this miracle to market in a widely accessible way a serious challenge.
OncoBay Clinical, a CRO specializing in complex immuno-oncology programs, has recently partnered with physIQ to make immuno-oncology trials, and ultimately marketed therapies, more accessible for patients through a predict-to-prevent safety monitoring solution using continuous remote patient data.
The webinar includes an explanation of the physIQ/OncoBay “physiology-first” data model and a demonstration of how physIQ’s continuous remote patient monitoring technology provides predictive patients insights for OncoBay’s clinical trial sponsors. We also discuss how this improved immuno-oncology trial model can have positive results such as: